Westfield Capital Management Co. LP lowered its position in shares of Omnicell, Inc. (NASDAQ:OMCL) by 16.8% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 798,212 shares of the company’s stock after selling 161,220 shares during the period. Westfield Capital Management Co. LP owned about 2.10% of Omnicell worth $40,749,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Schwab Charles Investment Management Inc. boosted its position in Omnicell by 2.1% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 162,614 shares of the company’s stock valued at $8,302,000 after buying an additional 3,273 shares during the period. WINTON GROUP Ltd purchased a new stake in Omnicell during the 3rd quarter valued at $2,189,000. Axiom International Investors LLC DE boosted its position in Omnicell by 43.3% during the 3rd quarter. Axiom International Investors LLC DE now owns 143,978 shares of the company’s stock valued at $7,350,000 after buying an additional 43,508 shares during the period. JPMorgan Chase & Co. boosted its position in Omnicell by 2.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 50,735 shares of the company’s stock valued at $2,517,000 after buying an additional 1,310 shares during the period. Finally, Legal & General Group Plc lifted its position in shares of Omnicell by 3.5% in the 3rd quarter. Legal & General Group Plc now owns 75,026 shares of the company’s stock worth $3,826,000 after purchasing an additional 2,562 shares during the period. 99.84% of the stock is owned by institutional investors and hedge funds.

Shares of Omnicell, Inc. (OMCL) opened at $52.30 on Monday. Omnicell, Inc. has a 12-month low of $31.85 and a 12-month high of $55.40. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.08 and a current ratio of 1.53.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, October 26th. The company reported $0.42 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.42. The company had revenue of $186.78 million during the quarter, compared to analyst estimates of $192.45 million. Omnicell had a negative net margin of 0.51% and a negative return on equity of 0.79%. Omnicell’s quarterly revenue was up 5.7% compared to the same quarter last year. During the same period last year, the business earned $0.40 EPS. equities research analysts expect that Omnicell, Inc. will post 0.12 EPS for the current fiscal year.

Several equities research analysts have recently commented on the stock. Craig Hallum reaffirmed a “buy” rating and issued a $62.00 target price (up from $52.00) on shares of Omnicell in a research report on Monday, October 30th. Oppenheimer reaffirmed a “buy” rating and issued a $55.00 target price on shares of Omnicell in a research report on Thursday, October 19th. Zacks Investment Research cut shares of Omnicell from a “hold” rating to a “strong sell” rating in a research report on Wednesday, November 1st. Benchmark raised their target price on shares of Omnicell from $55.00 to $67.00 and gave the stock a “buy” rating in a research report on Tuesday, September 5th. Finally, Cantor Fitzgerald raised their target price on shares of Omnicell to $58.00 and gave the stock an “overweight” rating in a research report on Friday, October 27th. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $54.86.

In related news, EVP Dan S. Johnston sold 14,613 shares of the stock in a transaction dated Friday, November 17th. The shares were sold at an average price of $47.81, for a total value of $698,647.53. Following the completion of the transaction, the executive vice president now directly owns 43,621 shares in the company, valued at approximately $2,085,520.01. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Gary S. Petersmeyer sold 1,000 shares of the stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $51.73, for a total transaction of $51,730.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 39,944 shares of company stock valued at $1,941,322. 3.77% of the stock is owned by company insiders.

ILLEGAL ACTIVITY WARNING: This report was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.watchlistnews.com/westfield-capital-management-co-lp-has-40-75-million-holdings-in-omnicell-inc-omcl/1742569.html.

About Omnicell

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).

Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.